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Abstract Post-translational modifications (PTMs) are covalent modifications in proteins during or after their 
 synthesis. Among them, the best known are phosphorylation, methylation, acetylation, and also 
cleavage or binding of small peptides (ubiquitination, SUMOylation and NEDDylation). Often the protein is modi-
fied in multiple sites and these modifications are coordinated generating a PTMs crosstalk.  Altered  patterns  
of PTMs  have been related to several pathologies. Currently, advances in mass spectrometry have made it 
possible to study multiple PTMs simultaneously. Oncology is one of the disciplines that incorporated these 
technologies for the need to better characterize tumors. In cancer, several alterations related to the ubiquitin- 
like PTMs have been described, such as SUMOylation. In particular, the interaction between different PTMs 
with SUMOylation has been studied in the context of the von Hippel Lindau (VHL) multitumoral syndrome, 
generating new putative biomarkers for the evolution of these tumors. RSUME or RWDD3, an enhancer of 
SUMOylation that acts on VHL and HIF proteins, shows a correlation with malignant parameters in this type 
of tumors, such as angiogenesis. Regulators of PTMs are becoming relevant as biomarkers in cancer. 
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Resumen Modificaciones en el proteoma celular y su aplicación en la clínica. Las modificaciones postraduc-
 cionales (PTMs por sus siglas en inglés) son modificaciones covalentes en las proteínas durante o 
posteriormente a su síntesis. Las más conocidas son fosforilación, metilación y acetilación, también clivajes o unión 
de pequeños péptidos (ubiquitinación, SUMOilación y NEDDilación). Frecuentemente la proteína es modificada 
en múltiples sitios y estas modificaciones se coordinan generando una interacción de PTMs. Patrones alterados 
de PTMs han sido relacionados con varias enfermedades. En la actualidad los avances en la espectrometría de 
masas han hecho posible estudiar en simultáneo múltiples PTMs. La oncología es una de las disciplinas que 
ha incorporado estas tecnologías por su necesidad de caracterizar a los tumores. En cáncer se han descripto 
varias alteraciones relacionadas a las PTMs del tipo ubiquitina como la SUMOilación. En particular la interacción 
entre distintas PTMs con la SUMOilación ha sido estudiada en el contexto de la enfermedad multitumoral de 
von Hippel Lindau, generando posibles nuevos biomarcadores para la evolución de estos tumores. RSUME o 
RWDD3, un enhancer de SUMOilación que actúa sobre las proteínas VHL y HIF, ha mostrado una correlación 
con parámetros malignos en este tipo de tumores, como la angiogénesis. Los reguladores de las PTMs están 
cobrando relevancia como biomarcadores en el cáncer. 
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Post-translational modifications (PTMs) are cova-
lent modifications that occur throughout the life of a 
protein, in the amino acids side chains or at the ends 
of the protein. These changes can take different forms: 
small chemical modifications such as phosphorylation, 
methylation, acetylation and also cleavages or binding 
of small peptides (ubiquitination, SUMOylation and 
NEDDylation), among others1. They can be considered 
as the last stage of gene expression and, more im-
portantly, they allow diversify the repertoire of proteins 
that can be generated and also understand the great 
discrepancy between the genotype and phenotypes ob-
served in both physiological and pathological conditions. 
The PTMs can be classified as irreversible (proteo-
lytic cleavages, cysteine oxidation, etc.) or reversible 
(phosphorylation, methylation, ubiquitination and SU-
MOylation, among others). Reversible modifications 
are particularly interesting since they are dynamically 
regulated for both specific conditions and the cell envi-
ronment allowing to modify the function, the interactions 
with DNA or with other proteins and macromolecules, as 
well as the activity, the subcellular localization and the 
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assembly in complexes of higher order of the proteins on 
which they occur1, 2. Historically, reversible PTMs were 
considered those catalyzed by enzymes and irreversible 
those that occur in response to spontaneous chemical 
reactions, such as the oxidation of cysteine to sulfonic 
acid. However, it is now known that some of these non-
enzymatic reactions previously considered as irreversible 
are regulated, for example, by the cellular redox state, 
and thus are in some cases reversible, reflecting a par-
ticular state of the cell and activating a response to this. 
To date, more than 200 PTMs have been found in 
humans3. Although the study of them occurs in a first 
stage at the level of individual modification in a protein 
residue, often the protein is modified in multiple sites, 
generating a code in which, through positive and nega-
tive interactions, these modifications are coordinated to 
determine the response, process called PTM crosstalk, 
as is clearly depicted in the histones code2. 
Post-translational modifications in 
medicine: relevance of post-translational 
modifications in pathologies 
As a consequence of the individual variability in response 
to therapies, the medical clinic approach has changed to 
a personalized medicine. This one and the translational 
research are focusing on finding the connection and 
relationship between genotype and phenotype. The 
study of the proteome, a protein set present in a cell at 
the time of analysis, arises from this perspective, which 
is ultimately, what defines the phenotype. For a given 
protein the combination of PTMs generates a variant 
different from the original and defines the function, 
the proteome includes as different variants all those 
proteins that have different PTMs. Altered patterns of 
PTMs have been related to several pathologies, whether 
they are cause or result, which makes them relevant 
targets for biomarkers studies and also pathogenesis 
studies1, 4. Currently, advances in mass spectrometry 
(MS), a technique that separate and identify proteins 
or fragments, has made it possible to simultaneously 
study multiple PTMs from small amounts of sample. 
This new approach, the quantitative PTMomic, has a 
great potential to discover biomarkers from body fluids 
and tissues, as well as elucidate the mechanisms of the 
disease through the subsequent investigation of signal-
ing pathways1. This new field also includes bioinformatics 
tools both for the identification of new PTMs and for the 
interpretation of results. Recently, numerous databases 
have been developed (reviewed in Pacovici, 2018) and 
can be classified into categories such as those used 
for the location and prediction of possible sites for 
modifications, for prediction of modified protein func-
tion and interaction and for visualization of the protein 
structure resulting from a PTM5. 
Among the post-translational modifications related to 
pathologies and studied in clinical samples have been 
described phosphorylation  associated with Alzheimer’s, 
diabetes and cancer, glycosylation that plays an impor-
tant role in cancer, in neurodegenerative diseases and 
inflammation, proteolytic cleavage that has been linked 
to cardiovascular disease, neurodegenerative inflamma-
tion and cancer4 and also ubiquitylation associated with-
autoimmune, neurodegenerative and cancer diseases5 . 
Post-translational modifications and cancer 
The relevance of studying PTMs in cancer relies in the 
searching for biomarkers for early detection5 and in the 
ability to select the appropriate therapeutic strategy to 
target molecular alterations. These tumor molecular 
alterations are continuously changing, increasing the 
heterogeneity of the cellular populations within it. These 
changes reflect the physiology of the patient and the dif-
ferent treatments he was exposed, among other factors. 
In some cases, these modifications are determined by 
mutations, a situation in which the genomic approach 
will provide important information but, in other cases, 
the spectrum of complex and heterogeneous muta-
tions makes it difficult to predict whether the presence 
of genetic anomalies will result in different levels of gene 
expression and in the cell phenotype. In addition, the 
tumor responds dynamically to a constantly changing 
environment, as the tumor microenvironment is, through 
the regulation of gene expression specified, ultimately, 
by PTMs. Thus, research in oncology has incorporated 
recent advances in technologies associated with pro-
teomics5, such as the of PTMs study for biomarkers in 
plasma of patients with glioblastoma recent ly approved 
by the FDA (Food and Drug Administration, USA)6.
 
Ubiquitin and Ubls (ubiquitin-like proteins)
in cancer
Ubiquitylation and conjugation of ubiquitin-like peptides 
(Ubl) involve a class of evolutionarily conserved peptides 
that are covalently conjugate to proteins and affect 
almost all aspects of cell regulation3. These include 
ubiquitin (Ub), Small ubiquitin-like modifier (SUMO), 
Neural precursor cell expressed, developmentally 
down-regulated 8 (NEDD8), Autophagy-related protein 8 
(ATG8), Autophagy related 12 (ATG12), HLA-F adjacent 
transcript 10 (FAT10), and Interferon-stimulated gene 
15 (ISG15), among others7. The conjugation pathways 
of these small tags typically require a cascade of reac-
tions carried out by: Ub or Ubls activating enzymes (E1), 
conjugating enzymes (E2) and ligases (E3). These three 
types of enzymes act sequentially. The tag is first acti-
vated by an E1 and then transferred to an E2 conjugate 
MEDICINA - Volumen 79 - N° 6/1 - NÚMERO ESPECIAL 80 ANIVERSARIO, 2019572
enzyme. Under certain conditions, E2 can conjugate 
directly to the target protein, but frequently it requires 
the cooperative activity of E3 ligases that interact at 
the same time with an E2 and substrate protein3. The 
different modifications with Ubls have differential roles. 
In the ubiquitylation process, depending on the Ub bond 
configuration, the polyUb chains can label the proteins 
for degradation through the 26S proteasome or they 
can act as intermediates for the formation of protein 
complexes. On the contrary, conjugation with a single 
Ub (monoubiquitylation) can regulate the activity or 
localization of proteins. Moreover, conjugation with the 
peptide SUMO is associated with the regulation of pro-
tein transcription and activity, complex formation and 
nuclear or cytoplasmic localization. While the NEDD8 
peptide is mainly conjugated with Cullin proteins to 
activate them for Ub conjugation, the Ubls ISG15 and 
FAT10 play a role in the innate immune response. Other 
notable Ubls are ATG8 and ATG12, which function in 
autophagy7 (Fig. 1). 
As a consequence of the diverse type of functions 
of this type of PTMs, alterations in the pathways as-
sociated with Ub and Ubl have been implicated in the 
pathogenesis of numerous human diseases such as 
cancer. Overexpression of several Ub E3 ligases has 
been reported in acute myeloid leukemia (WWP1), 
renal cell carcinoma (UBE3C), lymphoma and breast, 
pancreas, colon, and prostate cancer (Ubc13)5. Cancer 
has also been linked to the expression of enzymes 
involved in NEDDylation (e.g. NEDD8 E1, NAE1/UBA3 
and NEDD8 E2, BE2M/UBE2F) in several cancers such 
as lung, liver cancer and colorectal cancer, intra-hepatic 
cholangiocarcinoma, glioblastoma, and nasopharyngeal 
and esophageal squamous cell carcinomas8. Currently 
there are numerous chemotherapeutic agents that are 
being developed or that have already been approved 
and are involved in clinical trials focused on these PTMs. 
Although proteasome inhibitors (bortezomib/velcade/PS-
341 and carfizomib) are being used in the clinic, they 
are nonspecific and may cause side effects. In contrast, 
the substrate specificity of Ubls conjugating enzymes 
makes them an attractive target for treatment3. Since 
the E1 of Ub also show no specificity, similar to the 
proteasome inhibitors, the only inhibitor that is in phase 
II of trials is the MLN4924 (E1-inhibitor of NEDD8)9. In 
opposition, multiple drugs based on E3 ligases have been 
developed given the high specificity of these enzymes. 
GDC-199 (venetoclax) is a compound that inhibits 
There are different small peptide tags such as NEDD8, SUMO, ubiquitin 
(Ub), ATG8, ATG12, FAT10 and ISG15, which generate PTMs in a target 
protein and generally each family of tags is associated with a role on the 
protein.
Fig. 1.– Ubiquitin-like post-translational modifications (PTMs)
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SCFSKP2 activity, an E3 ligase of cell cycle regulators 
such as p27Kip1 and p21/Cip1, and has been shown 
good results in animal tests9. Nutlins is a cis-imidazoline 
analogue that inhibits MDM2 (E3 ligase of p53), whereas 
MI-219 inhibits the interaction between MDM2 and 
p53. Both inhibitors are currently being tested in clinical 
phase9. Related to the Ub system, the chemotherapy 
drugs development is currently focused  on compounds 
known  as PROTACs  (PROteolysis-TArgeting Chimeras) 
based on artificial molecules that recruit an Ub ligase 
to selectively degrade target proteins, not targeting the 
Ub system but rather using it as a tool.
Role of SUMOylation in cancer 
SUMOylation modulates a variety of biological pro-
cesses whose deregulation is closely related to the 
pathogenesis of cancer such as DNA damage repair, 
cell cycle progression and apoptosis, as well as pro-
cesses that have effects on tumor progression such as 
immune response, mitochondrial division regulation, 
voltage channels regulation and biological rhythms. The 
components of the SUMOylation pathway include the 
four paralogs of the SUMO peptide (SUMO1, SUMO2, 
SUMO3 and SUMO4), which require a cleavage by 
SENPs (setrin-specific proteases) proteins to be active. 
It also includes activating enzymes (SAE1 and SAE2) 
that transfer the peptide to the next enzyme called Ubc9 
conjugating enzyme, which binds the peptide to the sub-
strate (to date, only one conjugating enzyme has been 
described: Ubc9). In turn, there are enzymes E3 ligases 
(PIAS, RanBP2 and Pc2, among others) that favor 
conjugation. The expression of these ligases has been 
observed elevated in several malignant neoplasms and 
it is associated with a poor prognosis of the patient. By 
make use of SAE or UBC9 shRNAs, several groups 
have provided evidence that inhibition of the SUMO 
pathway inhibits tumor growth in mouse models10. In 
addition, the reduction of SAE confers synthetic lethality 
in tumors with high MYC activity or KRAS mutations, 
although several inhibitors of UBC9 (GSK145A, 2-D08 
and spectomycin B1) have been reported, their speci-
ficity is unclear and they seem to have low activity10. 
However, given the relevance of this PTM in cancer, 
the search for new inhibitors of these pathways remains 
a very active field. Considering that in comparison to 
ubiquitylation, SUMOylation confers greater stability 
and its main feature is modify the surface of its target 
proteins to regulate protein-protein interactions and 
thus, mediate the location and function, an alternative to 
the study of components involved in the SUMOylation 
is the study of interactors with the different enzymes 
of this pathway. 
RSUME role in cancer 
RSUME (RWD-containing SUMOylation enhancer) or 
RWDD3 is a protein identified from a tumor pituitary cell 
line with increased angiogenic  capacity and acts as a 
enhancer of SUMOylation cascade through a direct in-
teraction with the conjugating enzyme of SUMO, Ubc911. 
This protein has a RWD domain (RING finger and WD 
repeat containing proteins and DEAD-like helicases) 
which is essential for its activity and although exerts its 
effect mainly during the formation of the Ubc9-SUMO-1 
thioester bond, also acts in the transfer of SUMO-1 of 
the thioester bond to a specific substrate. It has been 
found expressed in different types of tumors such as 
gliomas, pituitary and pancreas neoplasias12, 13. In ad-
dition, RSUME has been associated with high risks of 
recurrence and metastasis in some tumors14. RSUME 
is intimately connected with the hereditary multitumoral 
syndrome of von Hippel Lindau (VHL), caused by muta-
tions in the VHL gene, since it is expressed in organs 
predisposed to the formation of VHL tumors and in he-
mangioblastomas and pheochromocytomas, characteris-
tic of this disease15. A bioinformatic analysis conducted 
by The Human Protein Atlas with a recent data set from 
The Cancer Genome Atlas Research Network (TCGA) 
shows that 20.1% of the 528 tumors samples of clear 
cell renal cancer studied, the main causes of death of 
VHL patients, expresses high levels of RSUME, and 
correlates with a 23% decrease in patient survival16. The 
VHL protein is a tumor suppressor. Interestingly, it is 
part of an Ub E3 ligase complex, which most studied 
target in cancer is the Hypoxia Inducible Factor, HIF-α, 
a protein that plays an important role in promoting tumor 
angiogenesis. Recently, RSUME has been reported as 
a regulator of this process, which makes it a promising 
target for future therapies as well as a biomarker in 
these types of cancer16 (Figure 2). Under normal oxygen 
conditions, enzymes called Prolyl Hydroxylases (PDH) 
catalyze the hydroxylation of prolines on HIF and allow 
its interaction with VHL, which acts as the recognition 
element o f  an  Ub3 E3 ligase complex and thus leads 
to HIF final degradation  by the proteasome. Multiple 
components of this system are SUMOylated, in the case 
of HIF-α this modification enhances its stability. RSUME 
is induced in hypoxia, increases the SUMOylation of 
HIF-α and VHL. VHL SUMOylation regulates its spatial 
distribution and reduces its interaction with HIF-α16. 
This regulation system involving VHL, HIF-α and 
RSUME is an example of multiple regulation nodes that 
occur in cellular processes and clearly illustrates the 
interrelation between a variety of PTMs in the cellular 
response induced by internal and external stimuli. The 
greater knowledge of these interconnections is an im-
portant tool for defining new cancer biomarkers based on 
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proteomic and PTMomic, as well as for the development 
of new therapeutic strategies. 
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